Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report

 
• By Sarah Karlin-Smith

Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.

Pills in Capitol Hill forecast
The CBO report probably won't change the forecast for Rx pricing legislation, but it will definitely hang in the air.

More from Pricing Debate

More from Market Access